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1718evaluated pre-treatment with ticagrelor. So the only
randomized trial to evaluate pre-treatment is the
ACCOAST study, which showed harm and no beneﬁt to
the patients with pre-treatment.
Finally, despite the caveats of the CURE and
CREDO trials, which favor pretreatment without
really testing the hypothesis, when pooling the data
from ACCOAST, CURE, and CREDO trials (N > 18,000),
there was no decrease in mortality or ischemic
events, but a signiﬁcant 45% excess of major bleeding
with thienopyridine pre-treatment (3). Both clopi-
dogrel and pre-treatment are strategies of the past
(4). However, we encourage Dr. Lozano to perform
the study that he suggests in his conclusion.*Gilles Montalescot, MD, PhD
*Institut de Cardiologie
Pitié-Salpêtri _ere University Hospital
47, Boulevard de l’Hôpital
75013 Paris
France
E-mail: gilles.montalescot@psl.aphp.fr
http://dx.doi.org/10.1016/j.jacc.2015.02.029
Please note: Dr. Montalescot has reported receiving consulting fees from Bayer,
Boehringer-Ingelheim, CFR, Europa, GLG, Iroko Cardio International, Lead-Up,
LLC, Luminex, McKinsey, Remedica, Servier, TIMI Group, WebMD, and
Wolters; consulting fees and grant support from Bristol-Myers Squibb, Astra-
Zeneca, Biotronik, Eli Lilly, The Medicines Company, Medtronic, Menarini,
Sanoﬁ, Pﬁzer, and Accumetrics; and grant support from Abbott Vascular,
Daiichi-Sankyo, Nanospheres, and Stentys.
RE F E RENCE S
1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on
myocardial revascularization: the Task Force on Myocardial Revascularization
of the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) developed with the special contribution of
the European Association of Percutaneous Cardiovascular Interventions
(EAPCI). Eur Heart J 2014;35:2541–619.
2. Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G. Pretreatment with
P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an
outdated and harmful strategy. Circulation 2014;130:1904–14.
3. Bellemain-Appaix A, Kerneis M, O’Connor SA, et al. Reappraisal of thieno-
pyridine pretreatment in patients with non-ST elevation acute coronary
syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269.
4. Rade JJ. Routine thienopyridine pretreatment for acute coronary
syndrome without ST elevation: it is time to rethink an ageing strategy. BMJ
2014;349:g6282.Not All NSTEMIs Are
Created EqualWe commend the authors of the recently published
ACCOAST-PCI (A Comparison of Prasugrel at the
Time of Percutaneous Coronary Intervention or as
Pre-treatment At the Time of Diagnosis in Patients
with Non-ST-Elevation Myocardial Infarction) study
(1) for their efforts. Despite being the largest
randomized trial of pre-treatment with prasugrelin non–ST-segment elevation myocardial infarction
(NSTEMI) patients, we have reservations that we
detail as follows.
Risk stratiﬁcation for adverse cardiac events is a key
component of treating NSTEMI patients. In this trial,
w57% of patients presentedwith ischemic ST-segment
changes and w23% with a GRACE (Global Registry of
Acute Coronary Events) score of more than 140. It
would be interesting to know the event rates in these
patients stratiﬁed according to whether they were
pre-treated with prasugrel or not. Ischemic events are
higher in patients with ischemic ST-segment changes
and/or high GRACE score, which may warrant more
aggressive therapy to improve outcomes (2).
The event rates for stent thrombosis were
extremely low, <0.5%. Because the trial was not
powered to show the differences between both
strategies, no real conclusions can be drawn about
stent thrombosis and the association with pre-
treatment with prasugrel other than numerically
there were fewer events in the pre-treatment group.*Ramez Nairooz, MD
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e139–228.REPLY: Not All NSTEMIs Are Created EqualTo answer the comments of Dr. Nairooz and col-
leagues, we have performed additional analyses of
the percutaneous coronary intervention subgroup
that need to be examined with caution considering
their post-hoc nature. Although it is possible to
evaluate the individual risk of a patient presenting
with a non–ST-segment elevation myocardial infarc-
tion according to well-known factors or scores, mak-
ing the decision to pre-treat or not, according to this
evaluation does not seem appropriate. The GRACE
